Search

Your search keyword '"Camm, A. John"' showing total 2,840 results
Start Over Author "Camm, A. John"
2,840 results on '"Camm, A. John"'

51. Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype

Author

Piccini, Jonathan P., Dufton, Christopher, Carroll, Ian A., Healey, Jeff S., Abraham, William T., Khaykin, Yaariv, Aleong, Ryan, Krueger, Steven K., Sauer, William H., Wilton, Stephen B., Rienstra, Michiel, van Veldhuisen, Dirk J., Anand, Inder S., White, Michel, Camm, A. John, Ziegler, Paul D., Marshall, Debra, Bristow, Michael R., and Connolly, Stuart J.

Published
2021
Full Text
View/download PDF

55. Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial

Author

Stambler, Bruce S, primary, Camm, A John, additional, Alings, Marco, additional, Dorian, Paul, additional, Heidbuchel, Hein, additional, Houtgraaf, Jaco, additional, Kowey, Peter R, additional, Merino, Jose L, additional, Mondésert, Blandine, additional, Piccini, Jonathan P, additional, Pokorney, Sean D, additional, Sager, Philip T, additional, Verma, Atul, additional, Wharton, J Marcus, additional, Bharucha, David B, additional, Plat, Francis, additional, Shardonofsky, Silvia, additional, Chen, Michael, additional, Ip, James E, additional, Jones, Alonzo, additional, Stambler, Bruce S, additional, Schleinkofer, David E, additional, Winters, Stephen, additional, Lam, Wilson, additional, Goldstein, Robert, additional, Dor, Isaac Dor, additional, Talwar, Sandeep, additional, O'Neill, Padraig G, additional, Koren, Michael J, additional, Beinart, Sean C, additional, Ambati, Srivani, additional, Mazer, Sean P, additional, Kinn, Robert M, additional, Roy, Karine, additional, Manshadi, Ramin, additional, Kuk, Richard, additional, Verma, Aditya, additional, Phelan, Timothy, additional, Stoian, Alexandru A, additional, Ellenbogen, Kenneth, additional, Jayachandran, J Vijay, additional, Connelly, Terence P, additional, Daccarett, Marcos, additional, Gandhi, Gaurang, additional, Mittal, Suneet, additional, Abdel-Wahab, Amir, additional, Augostini, Ralph, additional, Ip, John H, additional, Sorrentino, Denise, additional, Roux, Jean-Francois, additional, Brar, Ramandeep, additional, Khoo, Clarence, additional, Bennett, Matthew, additional, Lo, Eric, additional, Coutu, Benoit, additional, Sterns, Laurence, additional, Greer, Gerald S, additional, Gujja, Pradeep, additional, Gianfagna, Robert A, additional, Swarup, Vijendra, additional, Sogade, Felix, additional, Wilton, Stephen, additional, Ruisi, Christopher, additional, Barbera, Saverio, additional, Banchs, Javier E., additional, Korley, Victoria, additional, Schulze, Christopher, additional, Damle, Roger, additional, Healey, Jeffrey Sean, additional, Pandey, A Shekhar, additional, Anderson, Jeffrey L, additional, Venkatachalam, K L, additional, Noseworthy, Peter, additional, Friars, Douglas G, additional, Kambur, Thomas R, additional, Lockwood, Evan, additional, Meininger, Glenn, additional, Olsovsky, Greg, additional, Jones Sr, Alonzo, additional, Greer, Gerald, additional, Mehta, Rohit, additional, Akbar, Saleem, additional, Salman, Malik, additional, Rama, Bhola, additional, Arora, Ramesh, additional, Shah, Dhirenkumar, additional, Shah, Rakesh, additional, Cammarata, Michael, additional, Owens, Andrew, additional, Ludington, Katherine, additional, Wharton, Marcus, additional, Bagheri, Michael, additional, Khan, Mohammed, additional, Carr, Kenneth Warren, additional, Siddique, Sultan, additional, Parvathaneni, Sunthosh, additional, Devabhaktuni, Subodh, additional, Mouhaffel, Assad, additional, Mark, George, additional, Di Biase, Luigi, additional, Rangappa, Sunil, additional, Morton, Jared, additional, Yarmohammadi, Hirad, additional, Karim, Amin, additional, Martinez Fleites, Aldo, additional, Nero, Thomas, additional, Shafiq, Qaiser, additional, Pandey, Shekhar, additional, Khaykin, Yaariv, additional, Joza, Jacqueline, additional, Gosselin, Gilbert, additional, Skanes, Allen, additional, Vyselaar, John, additional, Savard, Daniel, additional, Xhaet, Olivier, additional, Catez, Emmanuel, additional, Vijgen, Johan, additional, Godart, Pascal, additional, Casado, Ruben, additional, Mairesse, Georges, additional, Rossenbacker, Tom, additional, Haemers, Peter, additional, Hoffer, Etienne, additional, Hausman, Pierre, additional, Vertes, Andras, additional, Duray, Gabor, additional, Szolnoki, Erzsebet, additional, Csanadi, Zoltan, additional, Lakatos, Ferenc, additional, Dorman, Reinhart, additional, Tuininga, Y S, additional, Jansen, W, additional, Velthuis, Sebastiaan, additional, van Bemmel, B, additional, Bech, Gerhard Jan Willem, additional, Pisters, Ron, additional, Valk, Suzanne, additional, Romer, Tjeerd, additional, Luermans, Justin, additional, Beelen, Driek, additional, van Eck, Martijn, additional, Vet, Thijs, additional, Shellings, Dirk, additional, Oosterhof, T, additional, Miekus, Pawel, additional, Bebenek, Waldemar, additional, Bielecka-Dabrowa, Agata, additional, Gniot, Jacek, additional, Zmuda, Witold, additional, Kasprzak, Michal, additional, Balak, Wojciech, additional, Ptaszynski, Pawel, additional, Nowak, Jacek, additional, Prokopczuk, Janusz, additional, Przybylski, Andrzej, additional, Wozniak-Skowerska, Iwona, additional, Derejko, Pawel, additional, Czarnecka, Danuta, additional, Janas, Adam, additional, Merino Llorens, Jose Luis, additional, Tercedor, Luis, additional, Iniguez Romo, Andres, additional, Ruiz Granell, Ricardo, additional, Gonzalez Juanatey, Jose Ramon, additional, Pascual-Figal, Domingo, additional, Martinez-Selles, Manuel, additional, Anguera Camos, Ignacio, additional, Ibanez Criado, Alicia, additional, Matrinez Basterra, Javier, additional, Izquierdo, Alvaro, additional, Rivas Gandara, Nuria, additional, Alegret Colome, Josep M, additional, Perez Diez, Diego, additional, Martínez Hervás, Miguel Ángel, additional, Medina, Maria, additional, Segura Saint-Gerons, Jose María, additional, Pedrote Leal, Alonso, additional, Fernandez Lozano, Ignacio, additional, Quesada, Aurelio, additional, Guerra Ramos, Jose, additional, Sarrias, Axel, additional, Ramos Maqueda, Javier, additional, Mansourati, Jacques, additional, Defaye, Pascal, additional, Guedon-Moreau, Laurence, additional, Milhem, Antoine, additional, De Guillebon, Maxime, additional, Chevalier, Philippe, additional, Badoz, Marc, additional, Kriatselis, Charalampos, additional, Simonis, Gregor, additional, Lewalter, Thorsten, additional, Zarse, Markus, additional, Wilke, Andreas, additional, Kraemer, Fabian, additional, and Al-Zoebi, Ayham, additional

Published
2023
Full Text
View/download PDF

59. Real-world utilization of the pill-in-the-pocket method for terminating episodes of atrial fibrillation: data from the multinational Antiarrhythmic Interventions for Managing Atrial Fibrillation (AIM-AF) survey

Author

Reiffel, James A, primary, Blomström-Lundqvist, Carina, additional, Boriani, Giuseppe, additional, Goette, Andreas, additional, Kowey, Peter R, additional, Merino, Jose L, additional, Piccini, Jonathan P, additional, Saksena, Sanjeev, additional, and Camm, A John, additional

Published
2023
Full Text
View/download PDF

60. PO-01-133 REAL-WORLD COMPARISON OF DRONEDARONE VS. SOTALOL IN ANTI-ARRHYTHMIC DRUG NAÏVE PATIENTS WITH ATRIAL FIBRILLATION

Author

Pundi, Krishna, primary, Fan, Jun, additional, Kabadi, Shaum, additional, Din, Natasha, additional, Blomström-Lundqvist, Carina, additional, Camm, A. John, additional, Kowey, Peter R., additional, Singh, Jagmeet P., additional, Rashkin, Jason, additional, Wieloch, Mattias, additional, Turakhia, Mintu P., additional, and Sandhu, Alexander, additional

Published
2023
Full Text
View/download PDF

61. MP-453091-1 EFFECT OF ETRIPAMIL NASAL SPRAY ON VENTRICULAR RATE IN PATIENTS EXPERIENCING SYMPTOMATIC ATRIAL FIBRILLATION

Author

Dorian, Paul, primary, Alings, Antonio M., additional, Coutu, Benoit, additional, Ip, James E., additional, Martinez, Felipe, additional, Piccini, Jonathan P., additional, Stambler, Bruce S., additional, Thermil, Nathalie, additional, Shardonofsky, Silvia, additional, Plat, Francis, additional, Bharucha, David B., additional, and Camm, A. John, additional

Published
2023
Full Text
View/download PDF

66. Systematic approach to outcome assessment from coded electronic healthcare records in the DaRe2THINK NHS-embedded randomized trial

Author

Wang, Xiaoxia, Mobley, Alastair R, Tica, Otilia, Okoth, Kelvin, Ghosh, Rebecca E, Myles, Puja, Williams, Tim, Haynes, Sandra, Nirantharakumar, Krishnarajah, Shukla, David, Kotecha, Dipak, Beatty, Susan, Mehta, Samir, Breeze, Sophie, Lancaster, Karen, Fordyce, Stuart, Allen, Naomi, Calvert, Melanie, Denniston, Alastair, Gkoutos, George, Jayawardana, Sahan, Ball, Simon, Baigent, Colin, Brocklehurst, Peter, Lester, Will, McManus, Richard, Seri, Stefano, Valentine, Janet, Camm, A John, Moore, Dame Julie, Rogers, Amy, Stanbury, Mary, Flather, Marcus, Walker, Suzy, and Wang, Duolao

Abstract

Aims Improving the efficiency of clinical trials is key to their continued importance in directing evidence-based patient care. Digital innovations, in particular the use of electronic healthcare records (EHRs), allow for large-scale screening and follow up of participants. However, it is critical these developments are accompanied by robust and transparent methods that can support high-quality and high clinical value research. Methods and results The DaRe2THINK trial includes a series of novel processes, including nationwide pseudonymized pre screening of the primary-care EHR across England, digital enrolment, remote e-consent, and ‘no-visit’ follow up by linking all primary- and secondary-care health data with patient-reported outcomes. DaRe2THINK is a pragmatic, healthcare-embedded randomized trial testing whether earlier use of direct oral anticoagulants in patients with prior or current atrial fibrillation can prevent thromboembolic events and cognitive decline (www.birmingham.ac.uk/dare2think). This study outlines the systematic approach and methodology employed to define patient information and outcome events. This includes transparency on all medical code lists and phenotypes used in the trial across a variety of national data sources, including Clinical Practice Research Datalink Aurum (primary care), Hospital Episode Statistics (secondary care), and the Office for National Statistics (mortality). Conclusion Co-designed by a patient and public involvement team, DaRe2THINK presents an opportunity to transform the approach to randomized trials in the setting of routine healthcare, providing high-quality evidence generation in populations representative of the community at risk.

Published
2022

67. Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD‐AF and ORBIT‐AF registries.

Author

Lim, Toon Wei, Camm, Alan John, Virdone, Saverio, Singer, Daniel E., Bassand, Jean P., Fonarow, Gregg C., Fox, Keith A. A., Ezekowitz, Michael, Gersh, Bernard J., Kayani, Gloria, Hylek, Elaine M., Kakkar, Ajay K., Mahaffey, Kenneth W., Pieper, Karen S., Peterson, Eric D., and Piccini, Jonathan P.

Subjects
ATRIAL fibrillation, ORAL medication, INTRACRANIAL hemorrhage, TRANSIENT ischemic attack, ANTICOAGULANTS
Abstract

Background: An unmet need exists to reliably predict the risk of intracranial hemorrhage (ICH) in patients with atrial fibrillation (AF) treated with oral anticoagulants (OACs). Hypothesis: An externally validated model improves ICH risk stratification. Methods: Independent factors associated with ICH were identified by Cox proportional hazard modeling, using pooled data from the GARFIELD‐AF (Global Anticoagulant Registry in the FIELD‐Atrial Fibrillation) and ORBIT‐AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) registries. A predictive model was developed and validated by bootstrap sampling and by independent data from the Danish National Patient Register. Results: In the combined training data set, 284 of 53 878 anticoagulated patients had ICH over a 2‐year period (0.31 per 100 person‐years; 95% confidence interval [CI]: 0.28–0.35). Independent predictors of ICH included: older age, prior stroke or transient ischemic attack, concomitant antiplatelet (AP) use, and moderate‐to‐severe chronic kidney disease (CKD). Vitamin K antagonists (VKAs) were associated with a significantly higher risk of ICH compared with non‐VKA oral anticoagulants (NOACs) (adjusted hazard ratio: 1.61; 95% CI: 1.25–2.08; p =.0002). The ability of the model to discriminate individuals in the training set with and without ICH was fair (optimism‐corrected C‐statistic: 0.68; 95% CI: 0.65–0.71) and outperformed three previously published methods. Calibration between predicted and observed ICH probabilities was good in both training and validation data sets. Conclusions: Age, prior ischemic events, concomitant AP therapy, and CKD were important risk factors for ICH in anticoagulated AF patients. Moreover, ICH was more frequent in patients receiving VKA compared to NOAC. The new validated model is a step toward mitigating this potentially lethal complication. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

68. Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the GARFIELD‐AF registry.

Author

Bassand, Jean‐Pierre, Virdone, Saverio, Camm, A. John, Fox, Keith A. A., Goldhaber, Samuel Z., Goto, Shinya, Haas, Sylvia, Hacke, Werner, Kayani, Gloria, Keltai, Matyas, Misselwitz, Frank, Pieper, Karen S., Turpie, Alexander G. G., Verheugt, Freek W. A., and Kakkar, Ajay K.

Subjects
ATRIAL fibrillation, PEOPLE with diabetes, STROKE, ANTICOAGULANTS
Abstract

Aims: This study aims to describe both management and prognosis of patients with diabetes mellitus (DM) and newly diagnosed atrial fibrillation (AF), overall as well as by antidiabetic treatment, and to assess the influence of oral anticoagulation (OAC) on outcomes by DM status. Methods: The study population comprised 52 010 newly diagnosed patients with AF, 11 542 DM and 40 468 non‐DM, enrolled in the GARFIELD‐AF registry. Follow‐up was truncated at 2 years after enrolment. Comparative effectiveness of OAC versus no OAC was assessed by DM status using a propensity score overlap weighting scheme and weights were applied to Cox models. Results: Patients with DM [39.3% oral antidiabetic drug (OAD), 13.4% insulin ± OAD, 47.2% on no antidiabetic drug] had higher risk profile, OAC use, and rates of clinical outcomes compared with patients without DM. OAC use was associated in patients without DM and patients with DM with lower risk of all‐cause mortality [hazard ratio 0.75 (0.69‐0.83), 0.74 (0.64‐0.86), respectively] and stroke/systemic embolism (SE) [0.69 (0.58‐0.83), 0.70 (0.53‐0.93), respectively]. The risk of major bleeding with OAC was similarly increased in patients without DM and those with DM [1.40 (1.14‐1.71), 1.37 (0.99‐1.89), respectively]. Patients with insulin‐requiring DM had a higher risk of all‐cause mortality and stroke/SE [1.91 (1.63‐2.24)], [1.57 (1.06‐2.35), respectively] compared with patients without DM, and experienced significant risk reductions of all‐cause mortality and stroke/SE with OAC [0.73 (0.53‐0.99); 0.50 (0.26‐0.97), respectively]. Conclusions: In both patients with DM and patients without DM with AF, OAC was associated with lower risk of all‐cause mortality and stroke/SE. Patients with insulin‐requiring DM derived significant benefit from OAC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

69. A randomized controlled trial to investigate the use of acute coronary syndrome therapy in patients hospitalized with COVID-19:the COVID-19 Acute Coronary Syndrome trial

Author

Kanagaratnam, Prapa, Francis, Darrel P, Chamie, Daniel, Coyle, Clare, Marynina, Alena, Katritsis, George, Paiva, Patricia, Szigeti, Matyas, Cole, Graham, de Andrade Nunes, David, Howard, James, Esper, Rodrigo, Khan, Masood, More, Ranjit, Barreto, Guilherme, Meneguz-Moreno, Rafael, Arnold, Ahran, Nowbar, Alexandra, Kaura, Amit, Mariveles, Myril, March, Katherine, Shah, Jaymin, Nijjer, Sukhjinder, Lip, Gregory YH, Mills, Nicholas, Camm, A John, Cooke, Graham S, Corbett, Simon J, Llewelyn, Martin J, Ghanima, Waleed, Toshner, Mark, Peters, Nicholas, Petraco, Ricardo, Al-Lamee, Rasha, Boshoff, Ana Sousa Marcelino, Durkina, Margarita, Malik, Iqbal, Ruparelia, Neil, Cornelius, Victoria, Shun-Shin, Matthew, Toshner, Mark [0000-0002-3969-6143], and Apollo - University of Cambridge Repository

Subjects
Aspirin, SARS-CoV-2, COVID-19, Bayes Theorem, Hemorrhage, anticoagulant agent, antiplatelet agent, ischemic heart disease, COVID-19 infection, Treatment Outcome, randomized controlled trial, Humans, Acute Coronary Syndrome, thrombosis
Abstract

BACKGROUND: Patients hospitalized with COVID-19 suffer thrombotic complications. Risk factors for poor outcomes are shared with coronary artery disease.OBJECTIVES: To investigate the efficacy of an acute coronary syndrome regimen in patients hospitalized with COVID-19 and coronary disease risk factors.METHODS: A randomized controlled, open-label trial across acute hospitals (United Kingdom and Brazil) added aspirin, clopidogrel, low-dose rivaroxaban, atorvastatin, and omeprazole to standard care for 28 days. Primary efficacy and safety outcomes were 30-day mortality and bleeding. The key secondary outcome was a daily clinical status (at home, in hospital, on intensive therapy unit admission, or death).RESULTS: Three hundred twenty patients from 9 centers were randomized. The trial terminated early due to low recruitment. At 30 days, there was no significant difference in mortality (intervention vs control, 11.5% vs 15%; unadjusted odds ratio [OR], 0.73; 95% CI, 0.38-1.41; p = .355). Significant bleeds were infrequent and were not significantly different between the arms (intervention vs control, 1.9% vs 1.9%; p > .999). Using a Bayesian Markov longitudinal ordinal model, it was 93% probable that intervention arm participants were more likely to transition to a better clinical state each day (OR, 1.46; 95% credible interval [CrI], 0.88-2.37; Pr [beta > 0], 93%; adjusted OR, 1.50; 95% CrI, 0.91-2.45; Pr [beta > 0], 95%) and median time to discharge to home was 2 days shorter (95% CrI, -4 to 0; 2% probability that it was worse).CONCLUSION: Acute coronary syndrome treatment regimen was associated with a reduction in the length of hospital stay without an excess in major bleeding. A larger trial is needed to evaluate mortality.

Published
2023

74. Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a <scp>post‐hoc</scp> analysis of the <scp>ATHENA</scp> trial

Author

Vaduganathan, Muthiah, Piccini, Jonathan P, Camm, A John, Crijns, Harry J G M, Anker, Stefan D, Butler, Javed, Stewart, John, Braceras, Rogelio, Albuquerque, Alessandro P A, Wieloch, Mattias, Hohnloser, Stefan H, MUMC+: MA Cardiologie (9), Cardiologie, and RS: Carim - H01 Clinical atrial fibrillation

Subjects
Aged, 80 and over, Heart Failure, Male, DEATH, Stroke Volume, Middle Aged, Prognosis, Atrial fibrillation, THERAPY, Ventricular Function, Left, Antiarrhythmic drugs, Ventricular Dysfunction, Left, Heart failure with preserved ejection fraction, Atrial Flutter, Humans, Female, Cardiology and Cardiovascular Medicine, Dronedarone, Aged
Abstract

AIMS: Limited therapeutic options are available for the management of atrial fibrillation/flutter (AF/AFL) with concomitant heart failure (HF) with preserved (HFpEF) and mildly reduced ejection fraction (HFmrEF). Dronedarone reduces the risk of cardiovascular events in patients with AF, but sparse data are available examining its role in patients with AF complicated by HFpEF and HFmrEF.METHODS AND RESULTS: ATHENA was an international, multicentre trial that randomized 4628 patients with paroxysmal or persistent AF/AFL and cardiovascular risk factors to dronedarone 400 mg twice daily versus placebo. We evaluated patients with (i) symptomatic HFpEF and HFmrEF (defined as left ventricular ejection fraction [LVEF] >40%, evidence of structural heart disease, and New York Heart Association class II/III or diuretic use), (ii) HF with reduced ejection fraction (HFrEF) or left ventricular dysfunction (LVEF ≤40%), and (iii) those without HF. We assessed effects of dronedarone versus placebo on death or cardiovascular hospitalization (primary endpoint), other key efficacy endpoints, and safety. Overall, 534 (12%) had HFpEF or HFmrEF, 422 (9%) had HFrEF or left ventricular dysfunction, and 3672 (79%) did not have HF. Patients with HFpEF and HFmrEF had a mean age of 73 ± 9 years, 37% were women, and had a mean LVEF of 57 ± 9%. Over a mean follow-up of 21 ± 5 months, dronedarone consistently reduced risk of death or cardiovascular hospitalization (hazard ratio 0.76; 95% confidence interval 0.69-0.84) without heterogeneity based on HF status (pinteraction >0.10). This risk reduction in the primary endpoint was consistent across the range of LVEF (as a continuous function) in HF without heterogeneity (pinteraction = 0.71). Rates of death, cardiovascular hospitalization, and HF hospitalization each directionally favoured dronedarone versus placebo in HFpEF and HFmrEF, but these treatment effects were not statistically significant in this subgroup.CONCLUSIONS: Dronedarone is associated with reduced cardiovascular events in patients with paroxysmal or persistent AF/AFL and HF across the spectrum of LVEF, including among those with HFpEF and HFmrEF. These data support a rationale for a future dedicated and powered clinical trial to affirm the net clinical benefit of dronedarone in this population.

Published
2022

75. Cost-effectiveness of early rhythm control vs. usual care in atrial fibrillation care: an analysis based on data from the EAST-AFNET 4 trial

Author

Gottschalk, Sophie, primary, Kany, Shinwan, additional, König, Hans-Helmut, additional, Crijns, Harry JGM, additional, Vardas, Panos, additional, Camm, A John, additional, Wegscheider, Karl, additional, Metzner, Andreas, additional, Rillig, Andreas, additional, Kirchhof, Paulus, additional, and Dams, Judith, additional

Published
2023
Full Text
View/download PDF

80. Clinical Guide to Cardiology

Author

Christian Fielder Camm, A. John Camm, Christian Fielder Camm, A. John Camm and Christian Fielder Camm, A. John Camm, Christian Fielder Camm, A. John Camm

Published
2016

81. Healthcare Resource Utilization in Patients with Newly Diagnosed Atrial Fibrillation: A Global Analysis from the GARFIELD-AF Registry

Author

Mantovani, Lorenzo G., Cozzolino, Paolo, Ferrara, Pietro, Virdone, Saverio, Camm, A. John, Verheugt, Freek W. A., Bassand, Jean-Pierre, Turpie, Alexander G. G., Hacke, Werner, Kayani, Gloria, Goldhaber, Samuel Z., Goto, Shinya, Pieper, Karen S., Gersh, Bernard J., Fox, Keith A. A., Haas, Sylvia, Eickels, Martin van, Kakkar, Ajay K., Investigators, on behalf of the GARFIELD-AF Investigators on behalf of the GARFIELD-AF, Mantovani, L, Cozzolino, P, Ferrara, P, Virdone, S, Camm, A, Verheugt, F, Bassand, J, Turpie, A, Hacke, W, Kayani, G, Goldhaber, S, Goto, S, Pieper, K, Gersh, B, Fox, K, Haas, S, van Eickels, M, and Kakkar, A

Subjects
Health Information Management, Leadership and Management, Health Policy, Health Informatics, Article, atrial fibrillation, healthcare resource utilization, inpatient care, outpatient care, ddc
Abstract

The management of atrial fibrillation (AF), the most common sustained arrhythmia, impacts healthcare resource utilization (HCRU). This study aims to estimate global resource use in AF patients, using the GARFIELD-AF registry. A prospective cohort study was conducted to characterize HCRU in AF patients enrolled in sequential cohorts from 2012 to 2016 in 35 countries. Components of HCRU studied were hospital admissions, outpatient care visits, and diagnostic and interventional procedures occurring during follow-up. AF-related HCRU was reported as the percentage of patients demonstrating at least one event and was quantified as rate-per-patient-per-year (PPPY) over time. A total of 49,574 patients was analyzed, having an overall median follow-up of 719 days. Almost all patients (99.5%) had at least one outpatient care visit, while hospital admissions were the second most frequent medical contact, with similar proportions in North America (37.5%) and Europe (37.2%), and slightly higher in the other GARFIELD-AF countries (42.0%; namely Australia, Egypt, and South Africa). Asia and Latin America showed lower percentages of hospitalizations, outpatient care visits, and diagnostic and interventional procedures. Analyses of GARFIELD-AF highlighted the vast AF-related HCRU, underlying significant geographical differences in the type, quantity, and frequency of AF-related HCRU. These differences were likely attributable to health service availability and differing models of care.

Published
2023

83. Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation: Results From the GARFIELD-AF Registry

Author

Bassand, Jean-Pierre, Virdone, Saverio, Goldhaber, Samuel Z., Camm, A. John, Fitzmaurice, David A., Fox, Keith A.A., Goto, Shinya, Haas, Sylvia, Hacke, Werner, Kayani, Gloria, Mantovani, Lorenzo G., Misselwitz, Frank, Pieper, Karen S., Turpie, Alexander G.G., van Eickels, Martin, Verheugt, Freek W.A., and Kakkar, Ajay K.

Published
2019
Full Text
View/download PDF

86. Combined atrial fibrillation ablation and left atrial appendage occlusion procedure in the United States: a propensity score matched analysis from 2016–2019 national readmission database

Author

Pasupula, Deepak Kumar, primary, Siddappa Malleshappa, Sudeep K, additional, Munir, Muhammad B, additional, Bhat, Anusha Ganapati, additional, Anandaraj, Antony, additional, Jakkoju, Avaneesh, additional, Spooner, Michael, additional, Koranne, Ketan, additional, Hsu, Jonathan C, additional, Olshansky, Brian, additional, and Camm, A John, additional

Published
2022
Full Text
View/download PDF

87. Consumer-Led Screening for Atrial Fibrillation: Frontier Review of the AF-SCREEN International Collaboration

Author

Brandes, Axel, primary, Stavrakis, Stavros, additional, Freedman, Ben, additional, Antoniou, Sotiris, additional, Boriani, Giuseppe, additional, Camm, A. John, additional, Chow, Clara K., additional, Ding, Eric, additional, Engdahl, Johan, additional, Gibson, Michael M., additional, Golovchiner, Gregory, additional, Glotzer, Taya, additional, Guo, Yutao, additional, Healey, Jeff S., additional, Hills, Mellanie T., additional, Johnson, Linda, additional, Lip, Gregory Y. H., additional, Lobban, Trudie, additional, Macfarlane, Peter W., additional, Marcus, Gregory M., additional, McManus, David D., additional, Neubeck, Lis, additional, Orchard, Jessica, additional, Perez, Marco V., additional, Schnabel, Renate B., additional, Smyth, Breda, additional, Steinhubl, Steven, additional, and Turakhia, Mintu P., additional

Published
2022
Full Text
View/download PDF

89. Data standards for atrial fibrillation/flutter and catheter ablation: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)

Author

Batra, Gorav, primary, Aktaa, Suleman, additional, Camm, A John, additional, Costa, Francisco, additional, Di Biase, Luigi, additional, Duncker, David, additional, Fauchier, Laurent, additional, Fragakis, Nikolaos, additional, Frost, Lars, additional, Hijazi, Ziad, additional, Juhlin, Tord, additional, Merino, José L, additional, Mont, Lluis, additional, Nielsen, Jens C, additional, Oldgren, Jonas, additional, Polewczyk, Anna, additional, Potpara, Tatjana, additional, Sacher, Frederic, additional, Sommer, Philipp, additional, Tilz, Roland, additional, Maggioni, Aldo P, additional, Wallentin, Lars, additional, Casadei, Barbara, additional, and Gale, Chris P, additional

Published
2022
Full Text
View/download PDF

91. Early Rhythm Control in Patients With Atrial Fibrillation and High Comorbidity Burden

Author

Rillig, Andreas, primary, Borof, Katrin, additional, Breithardt, Günter, additional, Camm, A. John, additional, Crijns, Harry J.G.M., additional, Goette, Andreas, additional, Kuck, Karl-Heinz, additional, Metzner, Andreas, additional, Vardas, Panos, additional, Vettorazzi, Eik, additional, Wegscheider, Karl, additional, Zapf, Antonia, additional, and Kirchhof, Paulus, additional

Published
2022
Full Text
View/download PDF

92. Identification of undiagnosed atrial fibrillation using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI) in primary care: cost-effectiveness of a screening strategy evaluated in a randomized controlled trial in England

Author

Hill, Nathan R., primary, Groves, Lara, additional, Dickerson, Carissa, additional, Boyce, Rebecca, additional, Lawton, Sarah, additional, Hurst, Michael, additional, Pollock, Kevin G., additional, Sugrue, Daniel M., additional, Lister, Steven, additional, Arden, Chris, additional, Davies, D. Wyn, additional, Martin, Anne-Celine, additional, Sandler, Belinda, additional, Gordon, Jason, additional, Farooqui, Usman, additional, Clifton, David, additional, Mallen, Christian, additional, Rogers, Jennifer, additional, Camm, A. John, additional, and Cohen, Alexander T., additional

Published
2022
Full Text
View/download PDF

93. Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference

Author

Schnabel, Renate B, primary, Marinelli, Elena Andreassi, additional, Arbelo, Elena, additional, Boriani, Giuseppe, additional, Boveda, Serge, additional, Buckley, Claire M, additional, Camm, A John, additional, Casadei, Barbara, additional, Chua, Winnie, additional, Dagres, Nikolaos, additional, de Melis, Mirko, additional, Desteghe, Lien, additional, Diederichsen, Søren Zöga, additional, Duncker, David, additional, Eckardt, Lars, additional, Eisert, Christoph, additional, Engler, Daniel, additional, Fabritz, Larissa, additional, Freedman, Ben, additional, Gillet, Ludovic, additional, Goette, Andreas, additional, Guasch, Eduard, additional, Svendsen, Jesper Hastrup, additional, Hatem, Stéphane N, additional, Haeusler, Karl Georg, additional, Healey, Jeff S, additional, Heidbuchel, Hein, additional, Hindricks, Gerhard, additional, Hobbs, F D Richard, additional, Hübner, Thomas, additional, Kotecha, Dipak, additional, Krekler, Michael, additional, Leclercq, Christophe, additional, Lewalter, Thorsten, additional, Lin, Honghuang, additional, Linz, Dominik, additional, Lip, Gregory Y H, additional, Løchen, Maja Lisa, additional, Lucassen, Wim, additional, Malaczynska-Rajpold, Katarzyna, additional, Massberg, Steffen, additional, Merino, Jose L, additional, Meyer, Ralf, additional, Mont, Lluıs, additional, Myers, Michael C, additional, Neubeck, Lis, additional, Niiranen, Teemu, additional, Oeff, Michael, additional, Oldgren, Jonas, additional, Potpara, Tatjana S, additional, Psaroudakis, George, additional, Pürerfellner, Helmut, additional, Ravens, Ursula, additional, Rienstra, Michiel, additional, Rivard, Lena, additional, Scherr, Daniel, additional, Schotten, Ulrich, additional, Shah, Dipen, additional, Sinner, Moritz F, additional, Smolnik, Rüdiger, additional, Steinbeck, Gerhard, additional, Steven, Daniel, additional, Svennberg, Emma, additional, Thomas, Dierk, additional, True Hills, Mellanie, additional, van Gelder, Isabelle C, additional, Vardar, Burcu, additional, Palà, Elena, additional, Wakili, Reza, additional, Wegscheider, Karl, additional, Wieloch, Mattias, additional, Willems, Stephan, additional, Witt, Henning, additional, Ziegler, André, additional, Daniel Zink, Matthias, additional, and Kirchhof, Paulus, additional

Published
2022
Full Text
View/download PDF

96. LB-469807-05 OUTCOMES WITH AND WITHOUT ORAL ANTICOAGULATION IN PATIENTS WITH PRIOR STROKE AND DEVICE-DETECTED ATRIAL FIBRILLATION: THE NOAH-AFNET 6 TRIAL

Author

Diener, Hans, Lip, Gregory, Nikorowitsch, Julius, Becher, Nina, Blomström-Lundqvist, Carina, Camm, A. John, Chlouverakis, Gregory, Goette, Andreas, Schotten, Ulrich, Simantirakis, Emmanuel, Toennis, Tobias, Vardas, Panos, Zapf, Antonia, Sehner, Susanne, Schnabel, Renate B., Scherr, Daniel, Ozga, Ann-Kathrin, Bertaglia, Emanuele, Brandes, Axel, Dichtl, Wolfgang, Calvert, Melanie, Lubinski, Andrzej, Merkely, Bela, Mont, Lluis, Rajappan, Kim, Fierenz, Alexander, de Groot, Joris, Hermans, Astrid, Marijon, Eloi, Wichterle, Dan, Dan, Andrei, Sarkozy, Andrea, and Kirchhof, Paulus

Published
2024
Full Text
View/download PDF

97. Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference

Author

Kotecha, Dipak, Breithardt, Günter, Camm, A John, Lip, Gregory Y H, Schotten, Ulrich, Ahlsson, Anders, Arnar, David, Atar, Dan, Auricchio, Angelo, Bax, Jeroen, Benussi, Stefano, Blomstrom-Lundqvist, Carina, Borggrefe, Martin, Boriani, Giuseppe, Brandes, Axel, Calkins, Hugh, Casadei, Barbara, Castellá, Manuel, Chua, Winnie, Crijns, Harry, Dobrev, Dobromir, Fabritz, Larissa, Feuring, Martin, Freedman, Ben, Gerth, Andrea, Goette, Andreas, Guasch, Eduard, Haase, Doreen, Hatem, Stephane, Haeusler, Karl Georg, Heidbuchel, Hein, Hendriks, Jeroen, Hunter, Craig, Kääb, Stefan, Kespohl, Stefanie, Landmesser, Ulf, Lane, Deirdre A, Lewalter, Thorsten, Mont, Lluís, Nabauer, Michael, Nielsen, Jens C, Oeff, Michael, Oldgren, Jonas, Oto, Ali, Pison, Laurent, Potpara, Tatjana, Ravens, Ursula, Richard-Lordereau, Isabelle, Rienstra, Michiel, Savelieva, Irina, Schnabel, Renate, Sinner, Moritz F, Sommer, Philipp, Themistoclakis, Sakis, Van Gelder, Isabelle C, Vardas, Panagiotis E, Verma, Atul, Wakili, Reza, Weber, Evelyn, Werring, David, Willems, Stephan, Ziegler, André, Hindricks, Gerhard, and Kirchhof, Paulus

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results